Insights On Enterprise Solutions

  1. Developing Analytical Methods For Advanced ADCs 10/22/2025

    Advanced molecules, especially ADCs with novel constructs, require extensive characterization testing. In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) discuss the nuances of analytical methodology for advanced ADCs and emphasize the importance of potency assays. They also share their thoughts on how much CMC development companies should aim to do internally before working with development partners.

  2. CMC Challenges Facing Next-Generation ADCs 10/22/2025

    In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) weigh in on the biggest challenges to ADC development, particularly navigating geopolitical tensions in a time of increasingly global manufacturing operations.

  3. Game-Changing CLD Platforms: Strategies, Technologies, Workflows 10/21/2025

    Selecting the right cell line platform is complex. Learn how flexible strategies, integrated technologies, and expert workflows enable high productivity, rapid timelines, and a de-risked path to clinical success.

  4. Collaboration An Untapped Fuel For Driving Biopharma R&D 10/20/2025

    Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.

  5. medac CDMO Capacity Update October 2025: Fill/Finish 10/20/2025

    Find more than just reliable, flexible support along the entire value chain of injectables. Learn how dual-site EU-based operations provide scalable capacity and seamless global supply for your molecules.

  6. Regulatory Confidence, Manufacturing Excellence 10/20/2025

    With decades of experience, we offer a flexible and collaborative partnership model for manufacturing excellence that enables our clients to increase speed to market with full regulatory confidence.

  7. The Future Of CGT: Phase-Appropriate Plasmid DNA Manufacturing 10/16/2025

    Effective CGT development hinges on phase-appropriate manufacturing. Matching manufacturing rigor to the clinical phase ensures the right quality at the right time while reducing costs and accelerating timelines.

  8. From Concept To Market: Mammalian Protein Development And Manufacturing 10/16/2025

    With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.

  9. Mabion Capacity Update October 2025: Analytical Services 10/15/2025

    We offer an end-to-end solution, covering every stage of biologic drug development, from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control.

  10. KBI Biopharma Capacity Update October 2025: Analytical Services 10/15/2025

    Leveraging decades of expertise, analytical capabilities, and regulatory knowledge, we deliver phase-appropriate solutions that streamline development, reduce risk, and accelerate timelines from discovery through commercialization.